🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

#GU23 Masterful presentation by Daniel Petrylak Results from cohort 2 of TROPHY-U-01: ph 2 SG in PT-ineligible pts w/ mUC that progressed after CPI 32% of CR, mPFS of 5.6mo, mOS of 13.5mo Awaiting results from other cohorts! Yale Cancer Center OncoAlert

Daniel P. Petrylak, MD, on Prostate Cancer: Latest Data on Pembrolizumab Plus Docetaxel ascopost.com/videos/2023-as… #pcsm #prostatecancer #immunotherapy #oncology Daniel Petrylak Yale Cancer Center

New #JITC article: First-in-human, phase 1 study of PF-06753512, a vaccine-based immunotherapy regimen (VBIR), in non-metastatic hormone-sensitive biochemical recurrence and metastatic castration-resistant prostate cancer (mCRPC) bit.ly/42rwFDf Daniel Petrylak

Various Cancer Treatment Drugs Experiencing Nationwide Shortage nbcconnecticut.com/news/local/var…

Our own Michael Karellas, MD, and Daniel Petrylak, MD, were recently part of a prostate panel bringing awareness to the Retired Men's Association of Greenwich. @yalemed Greenwich Hospital Yale New Haven Health #CommunityEngagement

Another excellent session @ Pittsburgh Annual Oncology Symposium with GU updates & innovations highlighted by exceptional speakers Tian Zhang, MD, MHS Daniel Petrylak Leonard Appleman Risa Wong UPMC Hillman Cancer Center UTSW Simmons Cancer Center Yale Cancer Center Taofeek K Owonikoko OncoAlert

#auasummit24 Bladder Cancer Advocacy Network Amer. Urol. Assn. advocating on Capitol Hill for bladder cancer research as a line item in CDMRP. Research helps our patients!

Health-related Quality of Life (HRQoL) was maintained, and deterioration was delayed (EORTC QLQ-C30) with EV vs. chemotherapy in previously treated advanced #urothelialcarcinoma #bladdercancer (analysis of the EV301 phase III trial for post-platinum & PD1/L1 inhibitor treated

Right now at #AUASummit24 Daniel Petrylak, Toby Chai MD and Carlos Glender are discussing bladder cancer and the value of research advocacy. #AUA #Urology

The KEYNOTE-921 trial found no significant benefit in adding pembrolizumab to docetaxel for metastatic castration-resistant prostate cancer. Standard care remains unchanged. Read more from Dr. Daniel Petrylak : ascopost.com/news/march-202… Yale Urology #ProstateCancer

video.snapstream.net/Play/DoFwOfUY6…

I was on CNN last night talking about prostate cancer and Joe Biden’s diagnosis

share.google/syX8OmQyCqJdIz…

My interview on Newsmax yesterday Dr. Petrylak to Newsmax: No Way to Tell When Biden's Prostate Cancer Developed | Newsmax.com

I’m on Newsmax tonight with Gregg Kelly

#TesticularCancer is one of the most curable malignancies, but early detection plays a critical role. Listen to or read what Daniel Petrylak, MD, shared with OncLiveTV on why this matters ➡️onclive.com/view/dr-petryl… Yale School of Medicine|Yale Cancer Center|Smilow Cancer Hospital|Yale Medicine

.Daniel Petrylak, Yale Cancer Center, focuses on the role of PARP inhibitors in managing prostate cancer. #mCRPC #Urology #ProstateCancer

Lutetium-177 PSMA radioligand therapy advances to earlier #mCRPC setting. Daniel Petrylak Yale Cancer Center & Steven Finkelstein, MD, DABR, FACRO U.S. Urology Partners join Zach Klaassen Georgia Cancer Center to discuss #PLUVICTO's™ FDA approval for pre-chemotherapy mCRPC. #WatchNow >

Thank you to everyone that joined our networking dinner with our Fairfield County-based Smilow Cancer Hospital Genitourinary Cancers team at the Delamar Southport! FMI: bit.ly/SmilowGUFairfi… Smilow Cancer Hospital Yale School of Medicine Yale New Haven Hosp Yale Urology Fairfield County Medical Association William K. Oh MD Daniel Petrylak

Interdisciplinary #GUCancerForum 2025: New approaches to neoadjuvant therapy for #UrothelialCarcinoma. Presented by Daniel Petrylak Yale Cancer Center. Written coverage by Zach Klaassen Georgia Cancer Center bit.ly/3HMlijr